by Marisa Wexler, MS | Jan 8, 2026 | Myeloma News
TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival in a mouse model of glioblastoma. That’s according to the study, “Nanotherapy Targeting miR-10b Improves Survival in...
by MM360 Staff | Jan 8, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Jan 7, 2026 | Myeloma News
Ernexa Therapeutics is making headway on plans to start clinical testing of ERNA-101, its stem cell therapy designed to treat ovarian cancer. The U.S. Food and Drug Administration (FDA) at a recent meeting “provided strong regulatory alignment on Ernexa’s development...
by MM360 Staff | Jan 7, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Jan 6, 2026 | Myeloma News
Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival of cells in the body — may help eliminate myeloma cells that are resistant to conventional treatments, according to a new study led by U.S....
by Marisa Wexler, MS | Jan 5, 2026 | Myeloma News
A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a type of blood cancer, is nearing its end, according to an update from the therapy’s developer, Sellas Life Sciences. The Phase 3 trial,...
